Evaluation of the clinical usefulness of rupatadine in patients with seasonal allergic rhinitis
- Conditions
- Seasonal allergic rhinitis
- Registration Number
- JPRN-UMIN000031360
- Lead Sponsor
- Medical Corporation Shinanokai, Shinanozaka Clinic
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Not provided
1) Patient with nasal disorders and/or infectious diseases. 2) Patient with non-allergic rhinitis. 3) Patient who underwent nasal surgery, including laser or coagulation surgery to improve nasal symptoms for less than one year before the agreement. 4) Patient with uncontrolled asthma. 5) Patient who has the hypersensitivity to antihistamine including rupatadine. 6) Following medications and treatments are prohibited before the start of the study. Antihistamine, leukotriene receptor antagonist, anti-thromboxane A2, and any antirhinitis medications. Steroid preparation (oral, injection, inhalation, and nasal drop), vasoconstictor (eye or nasal drop), parasympathetic nerve blocker (anti-cholinergic drug), biological preparation, immunosuppressive drug and any other drugs with similar pharmacological properties (eg Chinese herbal medicine), laser surgery, coagulation surgery, and nasal irrigation with normal saline. 7) Patient who is undergoing immunotherapy. 8) Patient with a liver or renal dysfunction. 9) Patient with severe complications. 10)Pregnant women or breast-feeding women, and patients who may be pregnant. 11) Patient who is judged to be ineligible for participation in the study by the clinical investigators.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Treatment satisfaction of the patient on the 11th day
- Secondary Outcome Measures
Name Time Method 1) Total nasal symptom score 2) Night nasal congestion score 3) QOL score